Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 15, Issue 3 (May 2013) 15, 309–313; 10.1038/aja.2013.29

Genetics and genomics of prostate cancer

Michael Dean1 and Hong Lou2

1 Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
2 Basic Science Program, SAIC-Frederick, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA

Correspondence: Dr M Dean, (deanm@mail.nih.gov)

Received 16 January 2013; Revised 25 February 2013; Accepted 26 February 2013 Advance online publication 8 April 2013

Abstract

Prostate cancer (PCa) is one of the most common malignancies in the world with over 890 000 cases and over 258 000 deaths worldwide each year. Nearly all mortalities from PCa are due to metastatic disease, typically through tumors that evolve to be hormone-refractory or castrate-resistant. Despite intensive epidemiological study, there are few known environmental risk factors, and age and family history are the major determinants. However, there is extreme heterogeneity in PCa incidence worldwide, suggesting that major determining factors have not been described. Genome-wide association studies have been performed and a considerable number of significant, but low-risk loci have been identified. In addition, several groups have analyzed PCa by determination of genomic copy number, fusion gene generation and targeted resequencing of candidate genes, as well as exome and whole genome sequencing. These initial studies have examined both primary and metastatic tumors as well as murine xenografts and identified somatic alterations in TP53 and other potential driver genes, and the disturbance of androgen response and cell cycle pathways. It is hoped that continued characterization of risk factors as well as gene mutation and misregulation in tumors will aid in understanding, diagnosing and better treating PCa.


Keywords:androgen receptor; cancer progression; chromatin remodeling; metastasis; prostate cancer (PCa); risk factor; somatic mutation; tumor heterogeneity

PDF | 中文摘要 |

 
Browse:  1112
Copyright 1999-2014    Shanghai Materia Medica, Shanghai Jiao Tong University.    All rights reserved